Abstracts tagged "osteoporosis"

Abstract Number: 1995 • 2012 ACR/ARHP Annual Meeting
What Are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs?
Nicole C. Wright¹, Ana Oliveira², Amy H. Warriner³, Jeffrey R. Curtis², Neil Binkley⁴, Steven R. Cummings⁵, Marc C. Hochberg⁶, Andrea LaCroix⁷, E. Michael Lewiecki⁸, John T. Schousboe⁹, Daniel H. Solomon¹⁰, Robert B. Wallace¹¹ and Kenneth G. Saag¹², ¹Epidemiology, The University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ⁴University of Wisconsin, Madison, WI, ⁵San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA, ⁶Department of Medicine, University of Maryland, Baltimore, MD, ⁷Department of Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁹Department of Rheumatology, Park Nicollet Health Services, Minneapolis, MN, ¹⁰Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ¹¹Public Health, University of Iowa, Iowa City, IA, ¹²Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Pragmatic clinical trials (PCTs) allow for study of real world patients using efficient study designs, facilitating comparative effectiveness research in resource constrained settings. Although…
Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Amy H. Warriner¹, Ryan C. Outman², Nathan Markward³, Ronald Aubert³, Jeffrey R. Curtis⁴, Robert Epstein³, Felix Freuh³, Julia McEachern³, David T. Redden⁵, Monika M. Safford², Eric Stanek³, Amy Steinkellner³ and Kenneth G. Saag⁶, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medco, Bethesda, MD, ⁴Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…
Abstract Number: 823 • 2012 ACR/ARHP Annual Meeting
Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis
Karine Briot¹, Thierry Schaeverbeke², Fabien Etchepare³, Philippe Gaudin⁴, Aleth Perdriger⁵, Muriel Vray⁶, Stephanie Rouanet⁷, Ghislaine Steinberg⁸ and Christian Roux¹, ¹Cochin hospital, Paris Descartes University, Paris, France, ²Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ³G.H. Pitié-Salpêtrière, Paris, France, ⁴Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Institut Pasteur, Paris, France, ⁷Medical Department, Roche, Boulogne-Billancourt, France, ⁸Medical Department, Roche, Neuilly sur Seine, France
Background/Purpose: The anti-IL6-R antibody tocilizumab (TCZ) is an effective treatment of rheumatoid arthritis (RA). Previous studies showed that TCZ has a positive effect on bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].